Lapatinib is an oral small-molecule epidermal growth factor tyrosine kinase inhibitor, generally used for treating human epidermal growth factor receptor 2 (HER2)-positive breast cancer and gastric cancer (17, 18). This evidence concerns the gene ERBB2 and gastric cancer.